Twiggy's Invex Therapeutics | The Imminent Coin Flip, page-120

IXC peaked at $1.40 in May 2020 and has only fallen over the subsequent 36 months. There can't be many left who have a positive association with this stock (apart from seed investors), so I don't think token $10-20k director purchases will change anything. $100-200k might be the minimum for the market to take notice.

Utlimately I think the low level of disclosure about trial recruitment is leading most to assume it means we aren't on track. Management teams usually only admit a trial is delayed when there is no mathematical way that they can deny it any longer.

There is nothing stopping IXC from disclosing enrolment numbers apart from their willingness to do so. I have concluded from this it meant that the trial will take longer than expected but didn't sell because I assumed it was already in the price. Big mistake!